Dyne Therapeutics joined PPMD for a presentation of clinical data from the DELIVER Trial of DYNE-251 in individuals living with Duchenne muscular dystrophy who are amenable to exon 51 skipping, first released on May 20th, 2024. These data demonstrated compelling impact on key disease biomarkers and trends in improvement of multiple functional endpoints.